TREE NEWS update: China’s National Medical Products Administration has approved Eli Lilly’s Class 1 innovative drug orforglipron calcium tablets, marketed as Muyouda, for long-term weight management in adults with a BMI of 30 kg/m² or higher (obesity) or 27 kg/m² or higher with weight-related conditions, alongside diet and exercise. The approval was granted to Eli Lilly Nederland B.V.
China NMPA Approves Eli Lilly’s Oral Weight-Loss Drug Orforglipron Calcium Tablets
AI take
The approval gives Eli Lilly a regulatory foothold in China's obesity market with an oral option, a formulation that could ease the cold-chain and injection-related barriers that have limited GLP-1 uptake. It matters most for the competitive positioning of injectable incumbents and for domestic developers racing to bring oral candidates to the same market. Whether the oral profile translates into broad prescribing under the BMI thresholds, and how pricing and reimbursement questions are handled in China, are the open questions worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
16m ago
Shandong Issues 7-Year 7.172B Yuan Shantytown Renovation Bond at 1.42%
26m ago
China Development Bank issues 15B yuan 1-year bond at 1.33%
30m ago
China’s Commerce Ministry says preparations for 10th CIIE have begun
34m ago
Foxconn: Memory and Component Shortages to Last Until 2027
35m ago
China Foreign Ministry Rejects US Discriminatory Lists on Chip Exports
36m ago
China Says It Is in Contact on China-Russia-US Leaders’ Meeting